M&T Bank Corp Has $1.94 Million Holdings in Corteva, Inc. $CTVA

Key Points

• M&T Bank cut its stake in Corteva by **98.5%** in Q4, selling 1,876,944 shares and leaving 28,910 shares valued at about **$1.94 million** per its SEC filing.
• Sell‑side sentiment is mildly positive with a MarketBeat consensus of **“Moderate Buy”** (14 Buy, 9 Hold) and a consensus target of **$85.19**, while recent price targets from Jefferies, Goldman Sachs and RBC were raised into the **$95–96** range.
• Corteva’s latest quarter matched EPS at **$0.22** but missed revenue ( $3.91B vs $4.23B expected); management set FY‑2026 guidance of **$3.45–3.70 EPS**, and the company declared a quarterly dividend of **$0.18** (0.9% yield).

M&T Bank Corp lessened its holdings in shares of Corteva, Inc. (NYSE:CTVA - Free Report) by 98.5% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 28,910 shares of the company's stock after selling 1,876,944 shares during the quarter. M&T Bank Corp's holdings in Corteva were worth $1,938,000 as of its most recent SEC filing.

Several other hedge funds have also added to or reduced their stakes in the business. State Street Corp raised its stake in Corteva by 3.6% during the 3rd quarter. State Street Corp now owns 35,280,805 shares of the company's stock worth $2,386,041,000 after buying an additional 1,230,074 shares during the period. Franklin Resources Inc. raised its stake in shares of Corteva by 5.9% in the 3rd quarter. Franklin Resources Inc. now owns 18,731,627 shares of the company's stock valued at $1,266,820,000 after purchasing an additional 1,051,389 shares during the period. Northern Trust Corp raised its stake in shares of Corteva by 1.8% in the 3rd quarter. Northern Trust Corp now owns 11,169,284 shares of the company's stock valued at $755,379,000 after purchasing an additional 194,728 shares during the period. Legal & General Group Plc raised its stake in shares of Corteva by 14.3% in the 3rd quarter. Legal & General Group Plc now owns 5,753,982 shares of the company's stock valued at $389,142,000 after purchasing an additional 720,469 shares during the period. Finally, Alliancebernstein L.P. raised its stake in shares of Corteva by 3.0% in the 3rd quarter. Alliancebernstein L.P. now owns 4,381,340 shares of the company's stock valued at $296,310,000 after purchasing an additional 125,690 shares during the period. Institutional investors and hedge funds own 81.54% of the company's stock.

Analyst Ratings Changes

CTVA has been the topic of several recent research reports. Weiss Ratings reissued a "hold (c)" rating on shares of Corteva in a research note on Wednesday, April 22nd. Jefferies Financial Group lifted their price target on Corteva from $85.00 to $95.00 and gave the company a "buy" rating in a research note on Monday, March 2nd. The Goldman Sachs Group lifted their price target on Corteva from $88.00 to $96.00 and gave the company a "buy" rating in a research note on Tuesday, April 14th. Zacks Research downgraded Corteva from a "strong-buy" rating to a "hold" rating in a research note on Friday, February 20th. Finally, Royal Bank Of Canada lifted their price target on Corteva from $89.00 to $95.00 and gave the company an "outperform" rating in a research note on Friday, April 24th. Fourteen equities research analysts have rated the stock with a Buy rating and nine have assigned a Hold rating to the company. According to MarketBeat, the company presently has a consensus rating of "Moderate Buy" and a consensus target price of $85.19.

Corteva Price Performance

Shares of NYSE CTVA opened at $78.95 on Wednesday. The stock has a market capitalization of $53.00 billion, a price-to-earnings ratio of 49.97, a PEG ratio of 2.72 and a beta of 0.68. The business has a 50-day moving average of $80.26 and a 200-day moving average of $71.94. The company has a debt-to-equity ratio of 0.07, a current ratio of 1.43 and a quick ratio of 0.96. Corteva, Inc. has a fifty-two week low of $60.53 and a fifty-two week high of $85.63.

Corteva (NYSE:CTVA - Get Free Report) last announced its quarterly earnings data on Tuesday, February 3rd. The company reported $0.22 earnings per share for the quarter, meeting the consensus estimate of $0.22. The company had revenue of $3.91 billion during the quarter, compared to analysts' expectations of $4.23 billion. Corteva had a return on equity of 9.06% and a net margin of 6.29%.Corteva's revenue for the quarter was down 1.7% compared to the same quarter last year. During the same quarter last year, the company earned $0.32 EPS. Corteva has set its FY 2026 guidance at 3.450-3.700 EPS. As a group, sell-side analysts predict that Corteva, Inc. will post 3.62 earnings per share for the current fiscal year.

Corteva Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Monday, June 15th. Stockholders of record on Monday, June 1st will be issued a $0.18 dividend. The ex-dividend date is Monday, June 1st. This represents a $0.72 annualized dividend and a dividend yield of 0.9%. Corteva's dividend payout ratio (DPR) is presently 45.57%.

Insider Buying and Selling at Corteva

In other news, insider Brian Titus sold 8,311 shares of the firm's stock in a transaction dated Friday, February 20th. The stock was sold at an average price of $76.55, for a total value of $636,207.05. Following the completion of the transaction, the insider owned 8,090 shares in the company, valued at $619,289.50. This trade represents a 50.67% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. 0.15% of the stock is owned by insiders.

Corteva Profile

Corteva, Inc NYSE: CTVA is an independent global agriculture company that was established as a publicly traded firm in mid‑2019 following the separation of the agriculture businesses from DowDuPont. The company focuses on delivering technologies and products that help farmers increase productivity and manage crop health. Corteva's operations combine seed genetics, crop protection chemistries, digital tools and biological solutions to address the full cycle of crop production.

Core business activities include research and development of seed genetics and trait technologies, formulation and sale of crop protection products (such as herbicides, insecticides and fungicides), and the development of seed treatments and biologicals.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.